Cargando…
Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies
Like Chinese boxes nesting inside each other, the classification of non-small cell lung cancer (NSCLC) is subdivided into smaller and smaller subtypes on the basis of histological and molecular attributes. The latter characterizes NSCLC by its molecular alterations and the identification of inhibito...
Autores principales: | Carter, Corey A., Zeman, Karen, Day, Regina M., Richard, Patrick, Oronsky, Arnold, Oronsky, Neil, Lybeck, Michelle, Scicinski, Jan, Oronsky, Bryan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5130044/ https://www.ncbi.nlm.nih.gov/pubmed/27007055 http://dx.doi.org/10.18632/oncotarget.8205 |
Ejemplares similares
-
Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapy
por: Oronsky, Bryan, et al.
Publicado: (2016) -
No patient left behind: The promise of immune priming with epigenetic agents
por: Carter, Corey A., et al.
Publicado: (2017) -
Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents
por: Oronsky, Bryan, et al.
Publicado: (2016) -
Rewriting the Epigenetic Code for Tumor Resensitization: A Review
por: Oronsky, Bryan, et al.
Publicado: (2014) -
Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man—PFS2: A Measure of Therapeutic Action-At-A-Distance
por: Oronsky, Bryan, et al.
Publicado: (2015)